Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
157 hedge funds and large institutions have $1.39B invested in Clovis Oncology, Inc. in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 51 reducing their positions, and 63 closing their positions.
66% more call options, than puts
Call options by funds: $47.8M | Put options by funds: $28.8M
12% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 51
18% less funds holding
Funds holding: 192 → 157 (-35)
51% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 63
54% less funds holding in top 10
Funds holding in top 10: 13 → 6 (-7)
57% less capital invested
Capital invested by funds: $3.27B → $1.39B (-$1.87B)
Top Buyers
| 1 |
PC
PointState Capital
New York
|
+$223M |
| 2 |
Goldman Sachs
New York
|
+$115M |
| 3 |
HM
HealthCor Management
New York
|
+$98.3M |
| 4 |
Millennium Management
New York
|
+$56.5M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$54.1M |
Top Sellers
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$76.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.6M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$40M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39.8M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$38.5M |
CLVS Hedge Fund Activity: Q4 2015 in Review
157 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2015, worth a combined $1.39B — down 57% from $3.27B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of CLVS and 31 opened new positions — a net loss of 32 holders — while 51 trimmed existing stakes and 57 added.
The largest buyer was PointState Capital, adding an estimated $223M. The largest seller was Viking Global Investors, exiting entirely with an estimated $76.9M sold.
- 157 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2015, down from 192 in Q3 2015.
- Funds reported $1.39B of Clovis Oncology, Inc. stock for Q4 2015, down 57% quarter-over-quarter.
- 31 funds opened new Clovis Oncology, Inc. positions in Q4 2015 and 63 closed out, a net change of -32 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2015 was PointState Capital, an estimated $223M added.
- The largest Clovis Oncology, Inc. seller in Q4 2015 was Viking Global Investors, an estimated $76.9M sold.
Based on aggregated 13F filings for Q4 2015.